Beacon Biosignals Raises $97 Million Series B

Beacon Biosignals extended its Series B round to $97 million.

The company's cumulative funding now exceeds $132 million after the extension.

New investors in the upsized round include JSL Health, Palo Santo VC, Kicker Ventures, and Samsung Next.